Scientists link brain microplastics to stroke and dementia, point to apheresis as removal path

By AI, Created 11:08 AM UTC, May 20, 2026, /AGP/ – An international Perspective published May 5, 2026 in the inaugural issue of Brain Health argues that human microplastic burden has become a brain health emergency. The paper ties microplastics to dementia, stroke and other outcomes, and says therapeutic apheresis is the most promising near-term removal strategy.

Why it matters: - The Perspective argues that microplastics in human tissue are no longer just an environmental issue; they are a direct brain health concern. - The paper connects microplastic burden to dementia, stroke, cognitive decline and mood disorders. - The authors say removal, not just exposure reduction, is emerging as the next clinical frontier.

What happened: - An international team from the USA, Germany and Canada published a Perspective on May 5, 2026 in the inaugural issue of Brain Health. - The article is titled “The human microplastic burden and brain health: from measurement to pathophysiology and removal.” - The paper is freely accessible online via the published Perspective. - The Perspective appears alongside the launch of Brain Health, a new peer-reviewed journal from Genomic Press focused on lifelong brain resilience.

The details: - Human brain tissue sampled from a 2016 to 2024 cohort carried microplastic concentrations seven to thirty times higher than matched liver or kidney samples. - Total tissue burden rose by about 50% across that eight-year span. - Donors diagnosed with dementia carried the highest brain microplastic loads. - Polyethylene was the dominant polymer, mostly in nanoscale, shard-like fragments. - In carotid endarterectomy patients, microplastics and nanoplastics were found inside atheromatous plaque. - Patients whose plaque tested positive had about a fourfold higher composite risk of myocardial infarction, stroke or death over 34 weeks of follow-up. - Mouse studies showed orally administered polystyrene nanoparticles crossed the blood-brain barrier within two hours. - The particles’ biomolecular corona appeared to help them enter the brain. - Larger particles did not cross, but nanoscale particles did. - Ultra-processed foods now supply more than half of U.S. caloric intake. - The Perspective says ultra-processed foods can drive exposure through packaging migration during heating and storage, industrial processing wear and downstream contamination. - Independent of microplastic content, ultra-processed food intake has been linked to depression, anxiety, cognitive decline, stroke and dementia. - A meta-analysis of 385,541 participants found a 53% increase in the odds of common mental disorder symptoms among people with the highest ultra-processed food intake. - UK Biobank data link the same dietary pattern to increased dementia risk. - REGARDS data showed that a 10% rise in relative ultra-processed food intake was associated with a 16% increase in cognitive impairment risk and an 8% increase in stroke risk, independent of Mediterranean, DASH or MIND diet adherence. - Bornstein and colleagues at University Hospital Carl Gustav Carus in Dresden reported that therapeutic apheresis can extract material consistent with microplastic particles from human plasma. - The authors say apheresis is biologically plausible, already available in tertiary centers and the most promising candidate intervention identified so far. - ARPA-H launched STOMP in April 2026 to target microplastics through better measurement, mechanism studies and clinical removal strategies. - The Perspective flags vulnerable groups including fetuses, children, patients with cerebrovascular disease and patients with neurodegenerative disease. - Microplastics have been localized in the intracellular compartment of human placenta, implying fetal exposure during neurodevelopment. - The paper says that, without a validated removal therapy, the only scalable exposure reduction measure now is lowering ultra-processed food consumption.

Between the lines: - The paper is trying to move the field from alarm to intervention. - The strongest claim is not that microplastics are proven causes of brain disease, but that the convergence of tissue measurements, vascular findings and animal transport data makes the risk too large to ignore. - The apheresis signal is promising, but the authors also acknowledge the field lacks validated, reproducible, polymer-specific measurement standards. - That measurement gap limits the ability to rank harms or prove that removal strategies work. - The policy implication is clear: public health exposure reduction is available now, while precision removal will need better analytics and clinical validation.

What’s next: - The authors say the next step is to validate microplastic measurements against standards the broader scientific community can accept. - Future work also needs to define how different polymers move through the body and which tissue compartments they affect. - Clinical testing must determine whether apheresis or other removal approaches actually reduce burden and improve outcomes. - The Perspective suggests scalable alternatives will be needed for different polymers, tissues and patient groups. - ARPA-H’s STOMP program may accelerate the measurement and removal agenda.

The bottom line: - Microplastics are moving from an environmental concern to a clinical research priority, with stroke and dementia now central to the debate.